Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Growth Metrics
Income Statement
Others
Ratios

Cresco Labs (CRLBF) Common Equity (2019 - 2025)

Cresco Labs (CRLBF) has disclosed Common Equity for 5 consecutive years, with $388.2 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Common Equity changed N/A year-over-year to $388.2 million, compared with a TTM value of $388.2 million through Dec 2024, changed N/A, and an annual FY2024 reading of $388.2 million, changed N/A over the prior year.
  • Common Equity was $388.2 million for Q4 2024 at Cresco Labs, down from $627.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $755.6 million in Q4 2021 and bottomed at $388.2 million in Q4 2024.
  • Average Common Equity over 4 years is $561.0 million, with a median of $550.1 million recorded in 2020.
  • The sharpest move saw Common Equity soared 152.96% in 2020, then dropped 17.01% in 2022.
  • Year by year, Common Equity stood at $473.2 million in 2020, then soared by 59.66% to $755.6 million in 2021, then dropped by 17.01% to $627.0 million in 2022, then crashed by 38.09% to $388.2 million in 2024.
  • Business Quant data shows Common Equity for CRLBF at $388.2 million in Q4 2024, $627.0 million in Q4 2022, and $755.6 million in Q4 2021.